Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity
- PMID: 8086134
- DOI: 10.1097/00002030-199406000-00007
Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity
Abstract
Objective: To determine the relationships between in vivo zidovudine (ZDV) phosphorylation in cells from HIV-infected patients and markers associated with disease progression and drug toxicity.
Design: A pharmacokinetic study of ZDV metabolism sponsored by the AIDS Clinical Trials Group (protocol 161). Plasma and intracellular pharmacokinetics following a 100 mg oral dose of ZDV were determined at weeks 4 and 24 of initial therapy in adult patients. Plasma concentrations and phosphorylated ZDV were determined by radioimmunoassay, and area under the concentration-time curves (AUC) were compared with clinical data collected during the pharmacokinetic study.
Setting: An outpatient setting at the University of Cincinnati AIDS Treatment Center, Cincinnati, Ohio, USA.
Patients: HIV-infected adults with CD4+ lymphocyte counts 200-500 x 10(6) cells/l with no prior history of anti-HIV therapy and no active infections requiring systemic therapy. Of 30 patients enrolled, 21 were evaluable.
Interventions: None.
Main outcome measures: AUC of plasma ZDV and intracellular total phosphorylated ZDV were compared with change from baseline of the following surrogate markers: CD4+ lymphocyte count, %CD4+ lymphocytes, CD4+/CD8+ cell ratio, serum beta 2-microglobulin, serum neopterin, neutrophils, red cell count, and hemoglobin.
Results: No correlations between plasma AUC and markers of therapeutic response were observed. However, significant positive correlations were observed between the AUC of total phosphorylated ZDV and changes in the %CD4+ lymphocytes and CD4+/CD8+ lymphocyte ratio; a negative correlation was observed with change in hemoglobin. Patients who responded to ZDV therapy, as measured by these variables, demonstrated significantly higher intracellular AUC (> 3 pmol x h/10(6) cells) than those who did not (approximately 2 pmol x h/10(6) cells).
Conclusions: The ability of HIV-infected patients to phosphorylate ZDV correlates with changes in markers associated with drug effect and toxicity. Potential individualization of therapy through monitoring of total phosphorylated ZDV in patients therefore warrants further exploration.
Similar articles
-
Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.Pediatr AIDS HIV Infect. 1997 Apr;8(2):120-6. Pediatr AIDS HIV Infect. 1997. PMID: 11361778
-
Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.BMJ. 1991 Jan 12;302(6768):73-8. doi: 10.1136/bmj.302.6768.73. BMJ. 1991. PMID: 1671651 Free PMC article.
-
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.Aust N Z J Med. 2000 Feb;30(1):11-20. doi: 10.1111/j.1445-5994.2000.tb01048.x. Aust N Z J Med. 2000. PMID: 10800872 Clinical Trial.
-
Zalcitabine.Ann Pharmacother. 1993 Apr;27(4):480-9. doi: 10.1177/106002809302700416. Ann Pharmacother. 1993. PMID: 8097417 Review.
-
Metabolism of Zidovudine.Gen Pharmacol. 1995 Nov;26(7):1469-75. doi: 10.1016/0306-3623(95)00047-x. Gen Pharmacol. 1995. PMID: 8690233 Review.
Cited by
-
Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.Drugs. 1998 Mar;55(3):383-404. doi: 10.2165/00003495-199855030-00005. Drugs. 1998. PMID: 9530544 Review.
-
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.J Clin Pharmacol. 2009 Sep;49(9):1079-90. doi: 10.1177/0091270009338482. Epub 2009 Jul 23. J Clin Pharmacol. 2009. PMID: 19628728 Free PMC article. Clinical Trial.
-
Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.Drugs. 1996 Aug;52(2):168-85. doi: 10.2165/00003495-199652020-00002. Drugs. 1996. PMID: 8841736
-
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20000887 Review.
-
Current knowledge and future prospects for the use of HIV protease inhibitors.Drugs. 1996 May;51(5):701-12. doi: 10.2165/00003495-199651050-00001. Drugs. 1996. PMID: 8861542 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials